Peptide profile · Weight Management
Mazdutide
Dual GLP-1/glucagon receptor agonist delivering up to 20% weight loss with superior glycemic control in clinical trials.
Written & reviewed by Michael Carroll · Research, Peptide Initiative
Typical dose
4 mg
Half-life
Approximately 8 days
Bioavailability
Subcutaneous bioavailability characteristic of acylated peptide analogs
Molecular weight
4563.1 Da
Evidence level
Strong human trials
01 · Compound profile
Scientific & efficacy data
Molecular formula
C210H322N46O67
Primary benefits
Phase 3 trials demonstrate up to 20.1% body weight reduction, among the highest in the dual agonist class.
Statistically superior HbA1c reductions versus both semaglutide and dulaglutide in head-to-head comparisons.
Glucagon receptor component drives hepatic fat reduction and improvements in lipid profiles beyond pure GLP-1 agonists.
Eli Lilly and Company / Innovent Biologics
Amino acid sequence
37-amino acid oxyntomodulin analog with Aib2 substitution and C18 diacid fatty acid acylation via PEG2 linker at Lys1002 · Dosing
How much do I take?
4 mg · once weekly
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
Best time to take
Administer Mazdutide at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
With food?
Mazdutide injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
If stacking
Mazdutide should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
＋ Increase if
- +You've tolerated the current dose for the recommended period without significant side effects
- +Therapeutic goals haven't been met at the current dose level
- +Your healthcare provider recommends dose escalation based on your response
- +Lab work or clinical assessments support a higher dose
－ Decrease if
- −Side effects are bothersome or impacting daily life despite management strategies
- −You experience any signs of an adverse reaction
- −Lab results indicate the need for dose reduction
- −Your healthcare provider recommends a lower dose based on your response
✓ Signs of right dose
- ✓Therapeutic goals being met with minimal side effects
- ✓Stable and consistent response to treatment
- ✓Lab values or clinical markers trending in the right direction
- ✓Good tolerance with manageable or absent side effects
Dosing Calculator
Calculate Your Exact Dose
Step 1: Peptide Weight
Find the weight printed on your peptide vial label
Look here!
The peptide weight is printed on the label
Look here!
The weight is on the label
Select Weight
Look for a number followed by 'mg' on the vial label (e.g., 5mg, 10mg)
03 · Suitability
Is this right for me?
Best for individuals seeking substantial weight loss exceeding 15% body weight & adults with type 2 diabetes requiring superior glycemic management
Best for
Individuals seeking substantial weight loss exceeding 15% body weight
Mazdutide is particularly well-suited for individuals focused on individuals seeking substantial weight loss exceeding 15% body weight. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Adults with type 2 diabetes requiring superior glycemic management
Mazdutide is particularly well-suited for individuals focused on adults with type 2 diabetes requiring superior glycemic management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Patients with obesity-related metabolic comorbidities
Mazdutide is particularly well-suited for individuals focused on patients with obesity-related metabolic comorbidities. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Those seeking dual-mechanism metabolic therapy
Mazdutide is particularly well-suited for individuals focused on those seeking dual-mechanism metabolic therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Mazdutide with similar peptides to find the best fit for your goals.
04 · Administration
How do I use it?
Subcutaneous injection
Reconstitution — what you need
Example
Add the recommended volume of bacteriostatic water to the Mazdutide vial. Gently swirl (do not shake) until the powder is fully dissolved. The resulting solution should be clear. Calculate your individual dose based on the concentration and your prescribed amount.
Your dose of Mazdutide is determined by your healthcare provider. Using an insulin syringe marked in units, draw up the exact amount prescribed. For example, if the reconstituted concentration is 1mg/mL and your dose is 0.5mg, draw up 0.5mL (50 units on an insulin syringe). Always double-check calculations before injection.
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Technique
- 01Wash your hands thoroughly with soap and water before handling supplies
- 02Clean the injection site with an alcohol swab and let it air dry completely
- 03Pinch a fold of skin at the chosen injection site
- 04Insert the needle at a 45-90 degree angle (depending on needle length and body composition)
- 05Inject the medication slowly and steadily over 5-10 seconds
- 06Release the skin fold and remove the needle, applying gentle pressure with a clean swab
- 07Rotate injection sites to prevent tissue irritation or lipodystrophy
- 08Dispose of the needle safely in a sharps container—never recap or reuse needles
Storage · before reconstitution
Store Mazdutide in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
Storage · after reconstitution
Once reconstituted, Mazdutide should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation
Sample daily schedule
05 · Safety
Is it safe?
3 common side effects · 2 serious
Mazdutide (Roche/Carmot GLP-1/GCG/GIP triple agonist) completed Phase Ib with generally favorable safety profile but dose-limiting gastrointestinal side effects. Nausea/vomiting occur in 40-50% of subjects at higher doses; weight loss averaging 12-18% observed. Pancreatitis risk monitoring required; calcitonin elevation consistent with GCG activation. Heart rate increases 5-8 bpm; no serious cardiac safety signals. Developmental program focuses on tolerability optimization.
Phase Ib data demonstrate triple receptor mechanism with dose-dependent HbA1c reductions (1.2-1.8%) and weight loss superior to GLP-1 monotherapy. Mechanistic studies using indirect calorimetry show increased energy expenditure and fat oxidation. Pancreatic imaging via MRI shows no structural abnormalities; serum lipase monitored for pancreatitis risk. Cardiovascular safety assessed via 24-hour ambulatory ECG shows sinus tachycardia without arrhythmias.
Common side effects · experienced by some users
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- ×Severe or worsening side effects that don't improve with dose adjustment or supportive care
- ×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- ×Your healthcare provider recommends discontinuation based on your clinical response
- ×Development of any new medical condition that may be contraindicated with Mazdutide
- ×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- ×Abnormal lab results or clinical markers that suggest adverse effects
Mazdutide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- ✓Metformin — May be used together under medical guidance.
- ✓Structured Exercise Program — May be used together under medical guidance.
- ✓SGLT2 Inhibitors — May be used together under medical guidance.
With medications
- !Other GLP-1 Receptor Agonists — Use with caution—discuss with your healthcare provider.
- !Sulfonylureas — Use with caution—discuss with your healthcare provider.
- !Insulin (without dose reduction) — Use with caution—discuss with your healthcare provider.
With supplements
- ✓Multivitamins — Generally safe to take alongside Mazdutide. Space doses apart if taking oral formulations to ensure optimal absorption.
- ✓Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
06 · Effectiveness
How do I know it's working?
Strong human trials · first signs weeks 1-4
Evidence level
Strong human trials
(Phase 3 or FDA approved)
How it works
Mazdutide is a dual-action peptide that activates both glucagon receptors and GLP-1 receptors in your body, creating a synergistic weight loss effect more powerful than either mechanism alone. It suppresses appetite through GLP-1 activation and increases metabolic rate through glucagon receptor activation, producing greater fat mobilization and weight loss compared to single-target GLP-1 drugs.
Mazdutide is a synthetic peptide agonist that simultaneously activates glucagon receptor (GcgR) and glucagon-like peptide-1 receptor (GLP-1R), both Gs-coupled GPCRs that increase cAMP and activate PKA signaling. GLP-1R activation in hypothalamic POMC neurons suppresses appetite and increases satiety signaling, while GcgR activation in hepatocytes and adipocytes increases gluconeogenesis, lipolysis, and fatty acid oxidation, increasing metabolic rate and energy expenditure. The dual agonism produces synergistic weight loss exceeding either mechanism alone: GLP-1 pathway provides appetite suppression (~15-20% weight loss), while GcgR activation provides metabolic acceleration (~8-12% additional weight loss), with combined effects potentially exceeding 20-25% weight loss in clinical trials. Glucose-dependent insulin secretion enhancement occurs through both pathways, providing glycemic control benefits.
What to expect
Weeks 1-4
What you might notice
- •Titration phase at 3 mg
- •Early appetite reduction and mild gastrointestinal adjustment
- •Initial weight loss of 2-4% typically observed
What's normal
- •Full integration of Mazdutide into physiological systems is established
- •Long-term Mazdutide response remains personalized to your physiology
- •Mazdutide tolerance is well-maintained with consistent dosing
What's next
- →Maintain your established Mazdutide protocol for sustained benefits
- →Continue periodic monitoring to confirm Mazdutide efficacy
- →Review comprehensive Mazdutide response with your provider
Weeks 4-16
What you might notice
- •Dose escalation to 4.5-6 mg
- •Progressive weight loss accelerates to 8-12%
- •Significant HbA1c reductions become apparent in diabetic patients
What's normal
- •Mazdutide is now achieving steady-state pharmacokinetics
- •Measurable changes aligned with Mazdutide's mechanism may appear
- •Initial adjustment effects typically resolve by this point
What's next
- →Maintain Mazdutide dosing exactly as established
- →Track progress toward intended outcomes in detail
- →Review lab work or biomarker changes with your healthcare team
Weeks 16-48+
What you might notice
- •Maintenance at 6-9 mg
- •Weight loss continues toward plateau of 15-20%
- •Metabolic parameters stabilize with sustained improvements in lipids, liver fat, and blood pressure
What's normal
- •Full therapeutic effects of Mazdutide are well-characterized at this point
- •Maintenance of Mazdutide's therapeutic effects is typical
- •Tolerance patterns with Mazdutide are generally stable over months
What's next
- →Comprehensive assessment of Mazdutide efficacy should be conducted
- →Discuss long-term continuation, cycling, or protocol modifications
- →Continue regular monitoring of relevant biomarkers or symptoms
Signs it's working · Treatment Response
- ✓Improvement in the primary symptoms or condition being treated
- ✓Positive changes in relevant lab values or clinical markers
- ✓Consistent, stable response to Mazdutide over time
- ✓Reduction in symptom frequency or severity
Signs it's working · General Well-being
- ✓Improved energy levels and daily functioning
- ✓Better quality of life related to the treated condition
- ✓Manageable or absent side effects indicating good tolerance
- ✓Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- •Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- •Insufficient time at target dose—most compounds need several weeks to show full benefits
- •Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- •Individual variation in response—genetics, metabolism, and other factors affect outcomes
- •Underlying conditions or medications interfering with absorption or effectiveness
- •Improper storage leading to degraded product—always verify proper storage conditions
Key research
07 · Questions
Frequently asked
How does mazdutide differ from semaglutide?+
Mazdutide is a dual GLP-1/glucagon receptor agonist, while semaglutide selectively targets only the GLP-1 receptor. The additional glucagon receptor activation in mazdutide increases hepatic fat oxidation and energy expenditure, potentially offering enhanced weight loss and liver fat reduction. In the DREAMS-3 head-to-head trial, mazdutide demonstrated statistically superior HbA1c reductions compared to semaglutide 1 mg.
Is mazdutide approved by the FDA?+
As of early 2026, mazdutide is not FDA-approved. It received approval from China's NMPA in June 2025 for chronic weight management and in September 2025 for type 2 diabetes, marketed as Xinermei. Regulatory submissions in other markets are anticipated based on ongoing global clinical programs.
What was the weight loss observed in clinical trials?+
In the GLORY-2 Phase 3 trial, mazdutide 9 mg achieved up to 20.1% mean body weight loss over the treatment period in adults with obesity. Earlier Phase 2 studies showed dose-dependent weight loss ranging from approximately 10% to 17% across dose groups.
Does mazdutide require dose titration?+
Yes. Mazdutide is initiated at 3 mg once weekly and gradually titrated upward through 4.5 mg and 6 mg to the target maintenance dose of up to 9 mg. This stepwise approach minimizes gastrointestinal side effects, particularly nausea and vomiting.
Can mazdutide be used for type 2 diabetes?+
Yes. Mazdutide is approved in China for type 2 diabetes and has demonstrated superior HbA1c reductions compared to both dulaglutide and semaglutide in Phase 3 DREAMS trials. Its dual mechanism provides glycemic control through both enhanced insulin secretion and reduced hepatic glucose output.
What are the main advantages of dual receptor agonism?+
Dual GLP-1/glucagon receptor agonism combines appetite suppression and glucose regulation from GLP-1 activation with increased energy expenditure, hepatic fat oxidation, and lipid metabolism enhancement from glucagon activation. This complementary mechanism may produce greater weight loss and more comprehensive metabolic improvement than selective GLP-1 agonists alone.
08 · Further reading
History & related research
History · since 2018
The Chinese Biotech That Beat The World to a New Drug Class
A young Chinese company races against global giants to develop the world's first dual GLP-1/glucagon agonist. In a stunning upset, Innovent Biologics reaches the finish line first — winning approval in China in June 2025 and proving that Asia's biotech industry has arrived on the world stage.
Read the full history of Mazdutide